Effect of zidovudine on the primary cytolytic T-lymphocyte response and T-cell effector function

Antimicrobial Agents and Chemotherapy

Volumn 44, Issue 7, 2000, Pages 1900-1905

  Francke, Sabine ^a,d   Orosz, Charles G ^a,b,c   Hayes, Kathleen A ^a   Mathes, Lawrence E ^a,c  

^a OHIO STATE UNIVERSITY   (United States)

^b THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^c OHIO STATE UNIVERSITY   (United States)

^d NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN; NUCLEOSIDE DERIVATIVE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ALLOIMMUNITY; ANIMAL CELL; ANIMAL MODEL; ANTIGEN SPECIFICITY; ARTICLE; CELLULAR IMMUNITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; FEMALE; HUMAN; IMMUNE DEFICIENCY; IMMUNOCOMPETENT CELL; IMMUNOTOXICITY; LYMPHOCYTE PROLIFERATION; LYMPHOCYTOTOXICITY; MAJOR HISTOCOMPATIBILITY COMPLEX RESTRICTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROLYMPHOCYTE; SPLEEN CELL; TARGET CELL;

ANIMALS; ANTI-HIV AGENTS; CELL DIVISION; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; ISOANTIGENS; MICE; MICE, INBRED DBA; T-LYMPHOCYTES, CYTOTOXIC; T-LYMPHOCYTES, REGULATORY; ZIDOVUDINE;

EID: 0033936488     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.44.7.1900-1905.2000     Document Type: Article

References (33)

1. Balzarini, J., R. Pauwels, M. Baba, P. Herdewlin, E. De Clercq, S. Broder, and D. G. Johns. 1988. The in vitro and in vivo anti-retrovirus activity, and intracellular metabolism of 3′-azido-2′,3′-dideoxythymidine and 2′,3′-dideoxycytidine are highly dependent on the cell species. Biochem. Pharmacol. 37:897-903.
2. Barile, M., D. Valenti, G. A. Hobbs, M. F. Abruzzese, S. A. Keilbaugh, S. Passarela, E. Quaglizriello, and M. V. Simpson. 1994. Mechanisms of toxicity of 3′-azido-3′-deoxythymidine: its interaction with adenylate kinase. Biochem. Pharmacol. 48:1405-1412.
3. + lymphocytes after HIV antiretroviral therapy reflects redistribution from lymphoid tissues. J. Clin. Investig. 103:1391-1398.
4. Centers for Disease Control. 1998. Public Health Service Task Force recommendations of the use of antiretroviral drugs in pregnant women infected with HIV-1 for maternal health and for reducing perinatal HIV-1 transmission in the United States. Morb. Mortal Wkly. Rep. 47:4-6.
5. Chandrasekaran, B., and T. E. Kute. 1995. Synchronization of cells in the S phase of the cell cycle by 3′-azido-3′-deoxythymidine: implications of cell cytotoxicity. Cancer Chemother. Pharmacol. 35:489-495.
6. Cload, P. A. 1989. A review of the pharmacokinetics of zidovudine in man. J. Infect. 18(Suppl. 1):15021.
7. Cockerell, G. L., E. A. Hoover, and S. krakowka. 1976. Lymphocyte mitogen reactivity and enumeration of circulating B-and T-cells during feline leukemia virus infection in the cat. J. Natl. Cancer Inst. 47:1995-1999.
8. Connor, E. M., R. S. Sperling, R. Gelber, P. Kiselev, G. Scott, M. J. O'Sullivan, R. VanDyke, M. Bey, W. Shearer, R. L. Jacobson, et al. 1994. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. N. Engl. J. Med. 331:1173-1180.
9. Dadaglio, G., F. Michel, P. Langlade-Demoyen, P. Sansonetti, D. Chevrier, F. Vuillier, F. Plata, and A. Hoffenbach. 1992. Enhancement of HIV-specific cytotoxic T lymphocyte responses by zidovudine (AZT) treatment. Clin. Exp. Immunol. 87:7-14.
10. Fazekas De St. Groth, S. 1982. The evaluation of limiting dilution assays. J. Immunol. Methods 49:R11-R23.
11. Heagy, W., C. Crumpacker, P. Lopez, and R. Finberg. 1991. Inhibition of immune function by antiviral drugs. J. Clin. Investig. 87:1916-1924.
12. Heeg, K., K. Deusch, W. Solbach, D. Bunjes, and H. Wagner. 1984. Frequency analysis of cyclosporine-sensitive cytotoxic T lymphocyte precursors. Transplantation 38:532-536.
13. Kalams, S. A., P. J. Goulder, A. K. Shea, N. G. Jones, A. K. Trocha, and B. D. Walker. 1999. Levels of human immunodeficiency virus type 1-specific cytotoxic T-lymphocyte effector and memory responses decline after suppression of viremia with highly active antiretroviral therapy. J. Virol. 73:6721-6728.
14. Lisignoli, G., M. C. Monaco, A. Degrassi, S. Toneguzzi, E. Ricchi, P. Costigliola, and A. Facchini. 1993. In vitro immunotoxicity of +/-2′-deoxy-3′-thiacytidine, a new anti-HIV agent. Clin. Exp. Immunol. 92:455-459.
15. Mathes, L. E., K. A. Hayes, P. J. Polas, and G. J. Kociba. 1996. Evidence that high-dosage AZT at the time of retrovirus exposure reduces antiviral efficacy. Antimicrob. Agents Chemother. 40:2183-2186.
16. Mathes, L. E., P. J. Polas, K. A. Hayes, C. L. Swenson, S. Johnson, and G. J. Kociba. 1992. Pre-and post-exposure chemoprophylaxis: evidence that 3′-azido-3′-dideoxythymidine (AZT) inhibits feline leukemia virus diseases by a drug-induced vaccine effect. Antimicrob. Agents Chemother. 36:2715-2721.
17. McKallip, R., M. Nagarkatti, and P. S. Nagarkatti. 1995. Immunotoxicity of AZT: inhibitory effect on thymocyte differentiation and peripheral T cell responsiveness to gp 120 of human immunodeficiency virus. Toxicol. Appl. Pharmacol. 131:53-52.
18. Mitsuya, H., K. J. Weinhold, P. A. Furman, M. H. St. Clair, S. N. Lehrman, R. C. Gallo, D. Bolognesi, D. W. Barry, and S. Broder. 1985. 3′-Azido-3′-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro. Proc. Natl. Acad. Sci. USA 82:7096-7100.
19. Moretta, A., G. Pantaleo, L. Maretta, J. Cerottini, and M. Mingari. 1983. Direct demonstration of the clonogenic potential of every human peripheral blood T cell. Clonal analysis of HLA-DR expression and cytolytic activity. J. Exp. Med. 157:743-754.
20. Mukherji, E., J. L.-S. Au, and L. E. Mathes. 1994. Differential antiviral activities and intracellular metabolism of 3′-azido-3′-deoxythymidine and 2′,3′-dideoxyinosine in human cells. Antimicrob. Agents Chemother. 38: 1573-1579.
21. Nunn, M. E., and R. B. Herberman. 1979. Natural cytotoxicity of mouse, rat, and human lymphocytes against heterologous target cells. J. Natl. Cancer Inst. 62:765-771.
22. Orosz, T., P. Adams, and R. Ferguson. 1988. Frequency of human alloantigen-reactive T lymphocytes. III. Evidence that cyclosporine has an inhibitory effect on human CTL and CTL precursors, independent of CsA-mediated helper T cell dysfunction. Transplantation 46(Suppl.):73S-79S.
23. Perryman, L. E., E. A. Hoover, and D. S. Yohn. 1972. Immunologic reactivity of the cat: immunosuppression in experimental feline leukemia. J. Natl. Cancer Inst. 49:1357-1365.
24. Riviere, Y., M. B. McChesney, F. Porrot, F. Tanneau-Salvadori, P. Sansonetti, O. Lopez, G. Pialoux, V. Feuillie, M. Mollereau, S. Chamaret, F. Tekaia, and L. Montagnier. 1995. Gag-specific cytotoxic responses to HIV type 1 are associated with a decreased risk of progression to AIDS-related complex and AIDS. AIDS Res. Hum. Retrovir. 11:903-907.
25. Ruprecht, R. M., L. G. O'Brien, L. D. Rossoni, and S. Nusinoff-Lehrman. 1986. Suppression of mouse viraemia and retroviral disease by 3′-azido-3′-deoxythymidine. Nature 323:467-469.
26. Ruprecht, R. M., S. Mullaney, L. D. Bernard, M. A. G. Sosa, R. C. Hom, and R. W. Finberg. 1990. Vaccination with a live retrovirus: the nature of the protective immune response. Proc. Natl. Acad. Sci. USA 87:5558-5562.
27. Shaw, D., D. Knight, A. Waterman, and J. Sommadossi. 1991. 3′-Azido-3′-deoxythymidine inhibition of human lymphocyte cytolytic function in vitro. Biochem. Pharmacol. 41:287-291.
28. Stine, K., D. Tyler, D. Stanley, J. Bartlett, D. Bolognesi, and K. Weinhold. 1991. The effect of AZT on in vitro lymphokine-activated killer (LAK) activity in human immunodeficiency virus type 1 (HIV-1) infected individuals. Cell. Immunol. 136:165-172.
29. Taswell, C. 1981. Limiting dilution assays for the determination of immunocompetent cell frequencies. I. Data analysis. J. Immunol. 126:1614-1619.
30. Tauris, P., B. Moller, C. Munck Petersen, and F. T. Black. 1989. Effects of 3′-azido-3′-deoxythymidine (AZT) on short-term cultured human peripheral blood lymphocytes. Eur. J. Clin. Investig. 19:167-171.
31. Tavares, L., C. Roneker, K. Johnston, S. Nusinoff Lehrman, and F. de Noronha. 1987. 3′-Azido-3′-deoxythymidine in feline leukemia virus-in-fected cats: a model for therapy and prophylaxis of AIDS. Cancer Res. 47:3190-3194.
32. Tornevik, Y., B. Ullman, J. Balzarini, B. Wahren, and S. Eriksson. 1995. Cytotoxicity of 3′-azido-3′-deoxythymidine correlates with 3′-azidothymidine-5′-monophosphate (AZTMP) levels, whereas anti-human immunodeficiency virus (HIV) activity corelates with 3′-azidothymidine-5′-triphosphate (AZTTP) levels in cultured CEM T-lymphoblastoid cells. Biochem. Pharmacol. 49:829-837.
33. Viora, M., G. Di Genova, R. Rivabene, W. Malorn, and A. Fattorossi, 1997. Interference with cell cycle progression and induction of apoptosis by dideoxynucleoside analogues. Int. J. Immunopharmacol. 19:311-321.